These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15888941)

  • 1. Postantifungal effect methods.
    Vitale RG
    Methods Mol Med; 2005; 118():153-8. PubMed ID: 15888941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium and zygomycetes.
    Vitale RG; Afeltra J; Meis JF; Verweij PE
    Mycoses; 2007 Jul; 50(4):270-6. PubMed ID: 17576318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An update on antifungal susceptibility testing].
    Tapia P CV
    Rev Chilena Infectol; 2009 Apr; 26(2):144-50. PubMed ID: 19621145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal combinations.
    Vitale RG; Afeltra J; Dannaoui E
    Methods Mol Med; 2005; 118():143-52. PubMed ID: 15888940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).
    Cuenca-Estrella M; Arendrup MC; Chryssanthou E; Dannaoui E; Lass-Florl C; Sandven P; Velegraki A; Rodriguez-Tudela JL;
    Clin Microbiol Infect; 2007 Oct; 13(10):1018-22. PubMed ID: 17697001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in antifungal susceptibility testing using CLSI reference and commercial methods.
    Cantón E; Espinel-Ingroff A; Pemán J
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):107-19. PubMed ID: 19622060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility testing methods of antifungal agents.
    Ernst EJ
    Methods Mol Med; 2005; 118():3-12. PubMed ID: 15888930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of the antimycotic activity of a thiophene derivative.
    Riviera L; Bellotti MG; Valenti G
    Chemioterapia; 1984 Apr; 3(2):116-8. PubMed ID: 6532537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis.
    Qiu WY; Yao YF; Zhu YF; Zhang YM; Zhou P; Jin YQ; Zhang B
    Curr Eye Res; 2005 Dec; 30(12):1113-20. PubMed ID: 16354625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibility of fungi isolated from clinical materials to voriconazole].
    Pawlik B; Szul A; Macura AB
    Med Dosw Mikrobiol; 2006; 58(2):155-61. PubMed ID: 17133909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determining the susceptibility of microfungi to antifungals and interpreting the results].
    Mallátová N
    Klin Mikrobiol Infekc Lek; 2007 Aug; 13(4):150-5. PubMed ID: 17929220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.
    Cuenca-Estrella M; Gomez-Lopez A; Gutierrez MO; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1062-5. PubMed ID: 18195057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Has a decade of standardizing antifungal sensitivity tests accomplished anything?].
    Rodríguez Tudela JL; Cuenca Estrella M
    Enferm Infecc Microbiol Clin; 2002 May; 20(5):191-3. PubMed ID: 12006254
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antifungigram: interpretation and choice of a technic].
    Vermorel O; Lebeau B; Claustre F; Grillot R
    Ann Biol Clin (Paris); 1989; 47(2):85-90. PubMed ID: 2735567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues in antifungal susceptibility testing.
    Johnson EM
    J Antimicrob Chemother; 2008 Jan; 61 Suppl 1():i13-8. PubMed ID: 18063599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal susceptibility testing method for resource constrained laboratories.
    Khan S; Singhal S; Mathur T; Upadhyay DJ; Rattan A
    Indian J Med Microbiol; 2006 Jul; 24(3):171-6. PubMed ID: 16912435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One.
    Carrillo-Muñoz AJ; Quindós G; Ruesga M; del Valle O; Pemán J; Cantón E; Hernández-Molina JM; Santos P
    Mycoses; 2006 Jul; 49(4):293-7. PubMed ID: 16784443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
    Sarifakioglu E; Seçkin D; Demirbilek M; Can F
    Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal activity of Crotalus durissus cumanensis venom.
    Magaldi S; Girón ME; Aguilar I; Rodriguez-Acosta A
    Mycoses; 2002 Feb; 45(1-2):19-21. PubMed ID: 11856432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE.
    Woyke T; Pettit GR; Winkelmann G; Pettit RK
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3580-4. PubMed ID: 11709343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.